CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population.
OBJECTIVE
The CYP19 gene encodes aromatase--a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa).


METHODS
Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%.


RESULTS
The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83).


CONCLUSIONS
The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.
Huang
Yu-Chuen
YC
Division of Preventive Medicine, Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Chen
Marcelo
M
Lin
Ming-Wei
MW
Chung
Ming-Yi
MY
Chang
Yen-Hwa
YH
Huang
William Ji-Shian
WJ
Wu
Tony T
TT
Hsu
Jong-Ming
JM
Yang
Stone
S
Chen
Yi-Ming Arthur
YM
D000368:Aged; D000369:Aged, 80 and over; D001141:Aromatase / Q000235:genetics*; D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D016001:Confidence Intervals; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000453:epidemiology*; D005838:Genotype; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D011336:Probability; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D012016:Reference Values; D018570:Risk Assessment; D013624:Taiwan / Q000453:epidemiology
D005819:Genetic Markers; D001141:Aromatase